Medicus Pharma's Non-Invasive Treatment Clears 73 Percent of Skin Lesions in Latest Trial

2026-03-18 companies

Toronto, Wednesday, 18 March 2026.
Medicus Pharma’s SkinJect therapy cleared 73 percent of lesions in a recent trial. This breakthrough suggests nearly three-quarters of patients might soon bypass immediate, invasive surgical interventions.

Unpacking the Phase 2 Clinical Data

The SKNJCT-003 study is a randomized, double-blind, three-arm Phase 2 clinical trial evaluating the efficacy of doxorubicin delivered directly into skin lesions via Medicus Pharma’s proprietary SkinJect microneedle platform [1][5]. Focused on patients with nodular basal cell carcinoma, the trial measured outcomes at Day 57 [1][5]. The results were striking: the cohort receiving a 200-µg dose of the drug-loaded microneedle array (D-MNA) demonstrated a 73 percent clinical clearance rate [1][5][6]. In comparison, a lower 100-µg dose achieved a 42 percent clinical clearance rate among the evaluated patients [4]. Furthermore, the active 200-µg cohort achieved a 40 percent histological clearance, confirming the eradication of cancerous cells at a microscopic level [5][6].

Market Potential and Upcoming Strategic Milestones

The commercial implications of a non-invasive treatment for non-melanoma skin diseases are substantial. Medicus Pharma estimates that basal cell carcinoma and Gorlin Syndrome represent a market opportunity of approximately $2 billion [5][6]. To address this, the company has established a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to the SkinJect therapy for patients suffering from multiple or inoperable basal cell carcinomas [1][5]. The biotechnology firm (NASDAQ: MDCX) aims to fast-track its clinical development program, with plans to convert the exploratory SKNJCT-003 trial into a pivotal study and secure an End of Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) in the first half of 2026 [1][5]. Expansion into the United Kingdom is also under consideration [1][5].

Valuation Disconnect and Broader Pipeline Ambitions

Despite the promising clinical data reported earlier this month, the equity market’s reaction has remained notably subdued. Medicus Pharma’s stock recently traded between $0.50 and $0.5456 per share, sitting well below its 200-day moving average of $2.10 [4][6]. This represents a steep discount, calculated as a drop of -74.019 percent relative to that moving average [6]. Following a recent decline on March 15, the company’s market capitalization hovered around $14 million to $14.7 million [4][6]. Financial analysts note that early-stage biotechnology firms often experience high price volatility [4]. Medicus Pharma reported a loss of $2.31 per share over the past 12 months, reflecting the heavy research and development costs typical of clinical-stage enterprises [4][GPT]. However, some market observers maintain price targets ranging from $6 to $27, suggesting significant upside potential if the clinical programs successfully navigate regulatory hurdles [4].

Sources

Biotechnology Medicus Pharma